A randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ethyl-ester omega-3 fatty acid in Taiwanese hypertriglyceridemic patients

Journal of Atherosclerosis and Thrombosis

Volumn 24, Issue 3, 2017, Pages 275-289

  Su, Ta Chen ^a,b   Hwang, Juey Jen ^a   Huang, Kuo Chin ^a   Chiang, Fu Tien ^a   Chien, Kuo Liong ^a,b   Wang, Kuo Yang ^c   Charng, Min Ji ^d   Tsai, Wei Chuan ^e   Lin, Lian Yu ^a   Vige, Runar ^f   Olivar, José Emilio Ruiz ^g   Tseng, Chuen Den ^a,h  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f Pronova BioPharma Norge AS   (Norway)

^g Ferrer Group   (Spain)

^h SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Ethnic chinese; Hypertriglyceridemia; Omacor; Omega 3 fatty acids

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 ACID ETHYL ESTER; PLACEBO; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; DOCOSAHEXAENOIC ACID; DRUG COMBINATION; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIETARY COMPLIANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; NAUSEA; RANDOMIZED CONTROLLED TRIAL; TAIWAN; WITHDRAWAL SYNDROME; BLOOD; CLINICAL TRIAL; DIETARY SUPPLEMENT; DRUG COMBINATION; LIFESTYLE; PATHOLOGY; SAFETY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; LIFE STYLE; MALE; MIDDLE AGED; SAFETY; SEVERITY OF ILLNESS INDEX; TAIWAN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 85014280942     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.34231     Document Type: Article

References (32)

1. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al.: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011; 123: 2292-2333
2. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, et al.: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J, 2011; 32: 1345-1361
3. Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM: Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother, 2008; 9: 1237-1248
4. Kris-Etherton PM, Harris WS, Appel LJ: Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol, 2003; 23: 151-152
5. Rupp H: Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia. Adv Ther, 2009; 26: 675-690
6. Davidson MH: Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol, 2006; 98(4A): 27i-33i
7. Berge RK, Madsen L, Vaagenes H, Tronstad KJ, Gottlicher M, Rustan AC: In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation. Biochem J, 1999; 343: 191-197
8. Nambi V, Ballantyne CM: Combination therapy with statins and omega-3 fatty acids. Am J Cardiol, 2006; 98(4A): 34i-38i
9. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, et al.: Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther, 2007; 29: 1354-1367
10. Tatsuno I, Saito Y, Kudou K, Ootake J: Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyl modification: The omega-3 fatty acids randomized double-blind (ORD) study. J Clin Lipidol, 2013; 7: 199-207
11. Pownall HJ, Brauchi D, Kilinc C, Osmundsen K, Pao Q, Payton-Ross C, et al.: Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis, 1999; 143: 285-297
12. Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, et al.: Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk, 1997; 4: 385-391
13. Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA, et al.: An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart, 2001; 85: 544-548
14. Balk E, Chung M, Lichtenstein A, Chew P, Kupelnick B, Lawrence A, et al.: Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Assess (Summ), 2004; 93: 1-6
15. Bradberry JC, Hilleman DE: Overview of omega-3 Fatty Acid therapies. P T, 2013; 38: 681-691
16. Harris WS, Connor WE, Inkeles SB, Illingworth DR: Dietary omega-3 fatty acids prevent carbohydrate-induced hypertriglyceridemia. Metabolism, 1984; 33: 1016-1019
17. Simopoulos AP: The importance of the ratio of omega-6/ omega-3 essential faty acids. Biomed & Pharmacother, 2002; 56: 365-379
18. Lin CY, Chen MF, Lin LY, Liau CS, Lee YT, Su TC: Insulin resistance is the major determinant for microalbumin-uria in severe hypertriglyceridemia: Implication for high-risk stratification. Int Med, 2008; 47: 1091-1097
19. Lee MJ, Chien KL, Chen MF, Stephenson DA, Su TC: Overweight modulates APOE and APOA5 alleles on the risk of severe hypertriglyceridemia. Clin Chim Acta, 2013; 416: 31-35
20. Ito R, Satoh-Asahara N, Yamakage H, Sasaki Y, et al.: An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia. J Atheroscler Thromb, 2014; 21: 248-260
21. Davidson MH, Maki KC, Bays H, Carter R, Ballantyne CM: Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol, 2009; 3: 332-340
22. Calabresi L, Donati D, Pazzucconi F, Sirtori CR, France-schini G: Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis, 2000; 148: 387-396
23. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M: Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol, 1996; 77: 31-36
24. Leigh-Firbank EC, Minihane AM, Leake DS, Wright JW, Murphy MC, Griffin BA, et al.: Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses. Br J Nutr, 2002; 87: 435-445
25. Maki KC, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM: Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to simvastatin therapy. Am J Cardiol, 2010; 105: 1409-1412
26. Tatsuno I, Saito Y, Ootake J: Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized long-term (ORL) study. J Clin Lipidol, 2013; 7: 615-625
27. Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR: Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol, 2008; 102: 429-433
28. Tatsuno I, Kudou K, Kagawa T: Effect of TAK-085 on low-density lipoprotein particle size in patients with hypertriglyceridemia: A double-blind randomized clinical study. Cardiovasc Ther, 2015; 33: 317-323
29. Austin MA, Breslow JL, Hennekens CH, Buring JE, Wil-lett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA, 1988; 260: 1917-1921
30. Ding C, Hsu SH, Wu YJ, Su TC: Additive effects of post-challenge hyperglycemia and low-density lipoprotein particles on the risk of arterial stiffness in healthy adults. Lipids Health Dis, 2014; 13: 179
31. Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, et al.: Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin, 2010; 26: 907-915
32. Kohashi K, Nakagomi A, Saiki Y, Morisawa T, et al.: Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. J Atheroscler Thromb, 2014; 21: 712-729